Softening up for a stink bid? The upshot of the ‘mistake’ at the start of Phase II is that Lumeda and others look set to establish the commercial potential of TLD-1433 in the biggest cancer killer of all before Theralase shareholders have even got to know whether it might or might not be a competitor in non muscle-invasive bladder cancer.
Add that to a sustained campaign to suppress the share price and we`re already seeing capitulation apathy from punch-drunk retail shareholders selling at 13 cents when their intuition tells them that it should be 13 dollars and talk from people who have been here for years of grateful acceptance of an offer of $2-$3 per share - valuing what may soon be shown to be the non-invasive destruction of deep cancers at less than a billion dollars.